bluebird bio Balance Sheet Health
Financial Health criteria checks 6/6
bluebird bio has a total shareholder equity of $222.5M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $613.6M and $391.1M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$174.29m |
| Equity | US$222.54m |
| Total liabilities | US$391.07m |
| Total assets | US$613.61m |
Recent financial health updates
Is bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?
Oct 13
Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation
Jul 13bluebird bio (NASDAQ:BLUE) Will Have To Spend Its Cash Wisely
Nov 08Recent updates
bluebird bio Is Priced Below IP Value
Mar 23Bluebird Bio: Innovative Therapies, Monetary Setbacks
Jan 25Is bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?
Oct 13Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation
Jul 13Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo
Oct 04Bluebird bio names interim finance chief
Sep 26Bluebird bio jumps 17% on FDA approval of new gene therapy
Sep 19bluebird bio' chief strategy and financial officer to depart
Sep 12FDA approves bluebird bio's Zyntego beti-cel gene therapy for beta thalassemia
Aug 17bluebird bio: Potential For 3 Gene Therapy Approvals In 12 Months Makes Buy Case
Jun 22bluebird bio: Beaten Down Biotech With Possible Long-Term Potential
May 09Bluebird Bio: Gene Therapy Launches Could Bring Big Revenues, Providing They Meet Approval
Feb 07bluebird bio: Ticker Fueled By Gambling Chance Of Commercial Success
Dec 12bluebird bio (NASDAQ:BLUE) Will Have To Spend Its Cash Wisely
Nov 08bluebird bio: Like A Bird In The Middle Of The Deep Blue Sea
Nov 03Financial Position Analysis
Short Term Liabilities: BLUE's short term assets ($247.1M) exceed its short term liabilities ($159.0M).
Long Term Liabilities: BLUE's short term assets ($247.1M) exceed its long term liabilities ($232.1M).
Debt to Equity History and Analysis
Debt Level: BLUE is debt free.
Reducing Debt: BLUE has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BLUE has sufficient cash runway for 7 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: BLUE is forecast to have sufficient cash runway for 6 months based on free cash flow estimates, but has since raised additional capital.